Adults with COPD who used inhaled corticosteroids for more than 24 months faced higher risks for diabetes, osteoporosis, ...

Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended ...

Considering all of the data and their limitations, questions still remain regarding the optimal treatment of COPD exacerbations ... reasonable to recommend oral corticosteroids when patient ...

Inhaled corticosteroids are often prescribed for chronic obstructive pulmonary disease but are not the first choice unless the patient has asthma-COPD overlap or frequent flare-ups. Chronic ...

Significantly greater composite adverse outcome rates seen for long- versus short-term inhaled corticosteroid use for prevalent, inception cohorts.

Long-term ICS use in COPD increases risks of severe health conditions like Type 2 diabetes and fractures. Read more!

The European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on maintenance for individuals with chronic obstructive pulmonary disease ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

"The steroids, that makes them hungrier ... In fact, some early studies show the drugs might reduce COPD flare-ups. More tests are underway.

Inhaled corticosteroids are often used outside of the recommended indications in COPD. Researchers revealed a link between long-term use and several risks for new diagnoses. Adults with COPD who ...

Long-term inhaled corticosteroid (ICS) treatment in COPD patients is linked to increased adverse outcomes, including type 2 diabetes, cataracts, pneumonia, osteoporosis, and nontraumatic fractures.